US 11,891,402 B2
Compositions and methods for treating cancer
Jonathan Ostrem, San Francisco, CA (US); Ulf Peters, San Francisco, CA (US); and Kevan M. Shokat, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Nov. 23, 2022, as Appl. No. 18/058,655.
Application 18/058,655 is a continuation of application No. 17/212,737, filed on Mar. 25, 2021, granted, now 11,603,376.
Application 17/212,737 is a continuation of application No. 16/720,526, filed on Dec. 19, 2019, granted, now 11,008,334, issued on May 18, 2021.
Application 16/720,526 is a continuation of application No. 16/013,271, filed on Jun. 20, 2018, abandoned.
Application 16/013,271 is a continuation of application No. 14/934,184, filed on Nov. 6, 2015, granted, now 10,023,588, issued on Jul. 17, 2018.
Application 14/934,184 is a continuation of application No. 14/391,369, abandoned, previously published as PCT/US2013/036031, filed on Apr. 10, 2013.
Claims priority of provisional application 61/794,956, filed on Mar. 15, 2013.
Claims priority of provisional application 61/728,145, filed on Nov. 19, 2012.
Claims priority of provisional application 61/622,507, filed on Apr. 10, 2012.
Prior Publication US 2023/0242548 A1, Aug. 3, 2023
Int. Cl. C07D 401/04 (2006.01); C07D 495/04 (2006.01); A61K 38/17 (2006.01); C07D 231/40 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 409/04 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/10 (2006.01); C07D 487/10 (2006.01); C07D 207/14 (2006.01); C07D 211/62 (2006.01); C07D 295/185 (2006.01); C07D 295/26 (2006.01); C07D 211/58 (2006.01); C07D 487/04 (2006.01); C12N 9/14 (2006.01); C07C 235/20 (2006.01); C07C 317/08 (2006.01); C12Q 1/6886 (2018.01)
CPC C07D 495/04 (2013.01) [A61K 38/1709 (2013.01); C07C 235/20 (2013.01); C07C 317/08 (2013.01); C07D 207/14 (2013.01); C07D 211/58 (2013.01); C07D 211/62 (2013.01); C07D 231/40 (2013.01); C07D 295/185 (2013.01); C07D 295/26 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 409/04 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C12N 9/14 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Y 306/05002 (2013.01); G01N 2500/04 (2013.01)] 27 Claims
 
1. A human K-Ras protein having a cysteine at residue 12, wherein said cysteine is covalently bonded to a compound, wherein said compound has the formula
R1-L1-L2-L3-E,
wherein
R1 is substituted or unsubstituted fused ring aryl or substituted or unsubstituted fused ring heteroaryl;
L1 is a substituted or unsubstituted heteroarylene;
L2 is a bond;
L3 is a substituted or unsubstituted spirocyclic linker; and, prior to covalently bonding to the cysteine 12,

OG Complex Work Unit Chemistry